Semaglutide vs. Wegovy: What's the Real Difference?

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is the active pharmaceutical ingredient; Wegovy is a branded injectable formulation of semaglutide approved by the FDA for chronic weight management. This distinction matters clinically because formulation, delivery mechanism, and dosing protocols affect both efficacy and individual tolerability profiles.

Many patients confuse the ingredient name with the product name, which can complicate informed decision-making. Understanding this relationship—and how different semaglutide formulations function—empowers you to have more informed conversations with your healthcare provider about which delivery method and dosing strategy aligns with your health profile.

What Is Semaglutide and How Does It Work?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist—a class of medications that mimics a naturally occurring hormone regulating appetite and blood sugar. It activates GLP-1 receptors in the brain, slowing gastric emptying and increasing satiety signaling, which reduces caloric intake and supports weight management.

Clinical data demonstrates semaglutide produces dose-dependent weight loss, with higher doses typically yielding greater reductions. The medication also improves cardiometabolic markers including fasting glucose, HbA1c, and blood pressure in many patients, extending benefits beyond weight management alone.

Semaglutide Formulations: Branded, Compounded, and Clinical Contexts

Semaglutide is available in multiple formulations and delivery routes, each with distinct FDA approvals, clinical uses, and cost profiles. Formulation differences affect absorption rate, onset of action, peak concentrations, and patient tolerability—factors that matter when optimizing individualized treatment.

Understanding which formulation may suit your clinical context requires discussion with a qualified provider who can evaluate your health status, treatment goals, and individual response patterns.

Formulation	Delivery Route	FDA Indication	Clinical Context
Wegovy	Weekly subcutaneous injection	Chronic weight management	Branded option; standard starting dose 0.25 mg, titrated to 2.4 mg
Ozempic	Weekly subcutaneous injection	Type 2 diabetes	Approved for glycemic control; off-label weight management use reported
Rybelsus	Oral tablet	Type 2 diabetes	First oral GLP-1 agonist; slower absorption; not approved for weight management
Compounded semaglutide	Injectable or oral (custom formulation)	Varies by clinical protocol	Licensed 503A pharmacy preparation; dosing customized per provider guidance

Key Clinical Differences Between Formulations

Branded formulations undergo standardized manufacturing, quality control, and regulatory oversight with established bioavailability data. Injectable semaglutide (Wegovy, Ozempic) achieves peak concentrations in 1–3 days; oral formulations (Rybelsus) require absorption enhancers and show lower bioavailability, making dosing less predictable.

Compounded semaglutide prepared by licensed 503A pharmacies offers customizable dosing and delivery options that may support more gradual titration protocols. Patients and providers should understand that compounded formulations are not FDA-approved but are prepared under pharmacy compounding regulations and should be sourced from licensed facilities with quality assurance processes in place.

Who Benefits From Semaglutide and Important Safety Considerations

Semaglutide is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It is contraindicated in personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or pregnancy. Common side effects include nausea, vomiting, constipation, and diarrhea, typically mild to moderate and often diminishing over time.

Treatment initiation and dose escalation should occur under qualified healthcare provider supervision. Your provider will evaluate your medical history, current medications, renal function, and individual risk factors to determine suitability and optimal formulation. Regular monitoring is essential to assess tolerability, efficacy, and metabolic outcomes.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test offered by PlexusDx may help provide context about your individual predispositions in key GLP-1 and weight-regulation pathways, including GLP1R, GIPR, FTO, and MC4R genetic variants. This information can support a more informed conversation with your provider about which semaglutide formulation and dosing protocol might align with your metabolic profile—though genetic predispositions should always be interpreted alongside clinical assessment and individual health status.

Understanding your genetic predispositions in peptide signaling pathways may help your provider anticipate potential tolerability patterns or metabolic response tendencies. For example, certain FTO or MC4R variants relate to appetite regulation biology. However, genetic information predicts predisposition patterns, not exact medication response; clinical response varies significantly based on individual physiology, lifestyle, and adherence.

When discussing semaglutide options with your provider, sharing genetic predisposition data alongside your medical history, prior medication responses, and treatment goals creates a more complete clinical picture. This integrated approach supports evidence-based, personalized treatment selection and may improve the likelihood of identifying a formulation and dosing strategy suited to your individual needs.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the most affordable GLP-1 option for semaglutide vs. wegovy: what's the real ?

PlexusDx offers compounded semaglutide starting at $149/mo and a Microdose GLP-1 Protocol from $129/month — both from licensed 503A compounding pharmacies, with no membership fee.

Does PlexusDx serve patients in all 50 states?

Yes. PlexusDx serves all 50 states. Five states require a scheduled live video consultation before the first prescription is issued; all others use async intake.

How does genetic testing improve GLP-1 outcomes?

Variants like GIPR rs1800437 affect GIP receptor function and predict differential response to tirzepatide versus semaglutide. PlexusDx's Precision Peptide Genetic Test evaluates 150+ relevant variants to guide medication selection.

Is compounded semaglutide the same as Wegovy or Ozempic?

Compounded semaglutide uses the same active ingredient but is not FDA-approved. It is prepared under federal compounding regulations at licensed 503A compounding pharmacies.

Can I use HSA or FSA funds to pay for PlexusDx?

Yes. Prescription GLP-1 medications from PlexusDx are HSA/FSA eligible with a valid prescription. PlexusDx accepts HSA and FSA cards directly at checkout.